Zheng Quan Ri Bao Wang·2025-08-29 10:58Core Insights - JD Health and Eli Lilly China have signed a strategic cooperation agreement to integrate quality medical resources and digital services for chronic disease management, focusing on obesity, diabetes, and alopecia [1][2] - Eli Lilly, a leading global pharmaceutical company with nearly 150 years of history, has made significant advancements in various fields, including diabetes and obesity, benefiting millions of patients worldwide [1] - The partnership aims to create a comprehensive management model that combines drug accessibility, health education, and digital services, enhancing patient trust and access to high-quality medications and healthcare services [1][2] Company Collaboration - JD Health will leverage its supply chain system to ensure stable direct supply of treatment products, supported by professional cold chain logistics for efficient and safe nationwide delivery [2] - The collaboration will include the establishment of a disease education section to improve patient awareness and self-management capabilities, along with online consultation and follow-up services through JD Internet Hospital [2] - Both companies will develop specialized tools and educational resources for healthcare professionals to enhance their diagnostic and management capabilities [2] Product Offerings - Eli Lilly has 25 products available for sale on JD Health, including the innovative drug Mounjaro (tirzepatide injection), which has gained significant attention since its launch on the platform [1] - The recent introduction of the multi-dose prefilled pen for Mounjaro provides patients with a more flexible and convenient medication option, enriching the treatment experience [1]